Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 11Recurrence 2Myelodysplastic Syndromes 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 33Cyclophosphamide 31fludarabine 19venetoclax 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × gilteritinib × Clear all
NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc.

Phase 1/2 Recruiting
606 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05279859 2022-06-15

HERKULES-4

Erasca, Inc.

Phase 1/2 Withdrawn
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡